Can Cas3 power a COVID/flu POCT?
CONAN uses type I CRISPR-Cas3 collateral ssDNA cleavage for rapid (~40 min), low-cost, instrument-free SARS-CoV-2 detection and IAV single-base discrimination.
Source
CRISPR-Cas3-based diagnostics for SARS-CoV-2 and influenza virus
What they did
Demonstrated target-activated nonspecific ssDNA cleavage by E. coli type I CRISPR-Cas3, then built CONAN combined with isothermal amplification for instrument-free readout on SARS-CoV-2 and influenza targets.
What they found
CONAN detected SARS-CoV-2 in clinical samples and specifically resolved single-base-pair mutations in IAV variants, positioning Cas3 alongside Cas12 DETECTR and Cas13 SHERLOCK as a CRISPR-dx option for hospital POCT.
The limits
What it doesn't show
Not a large multi-site regulatory trial; real-world sensitivity/specificity vs PCR across variants still need broader clinical evaluation.
Key terms
- CONAN
- Cas3-Operated Nucleic Acid detectioN diagnostic platform.
- Collateral cleavage
- Target-activated nonspecific cutting of reporter ssDNA.
- CRISPR-dx
- CRISPR-based diagnostic assays (e.g., DETECTR, SHERLOCK, CONAN).
- Isothermal amplification
- Nucleic-acid amp (e.g., RPA/LAMP) without thermal cycling.
- POCT
- Point-of-care testing near the patient.
Flashcards
Research intelligence for this paper
See its role on concept claims, tensions it is part of, placement history, and related discoveries.
Quiz yourself
CONAN is based on which CRISPR effector class emphasis?
Common questions
Assay name?
CONAN (Cas3-Operated Nucleic Acid detectioN).
Speed claim?
Rapid detection within about 40 minutes.
Pathogens highlighted?
SARS-CoV-2 and influenza A variants.
Special IAV capability?
Single-base-pair mutation discrimination.